Page last updated: 2024-11-04

trioxsalen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Trioxsalen: Pigmenting photosensitizing agent obtained from several plants, mainly Psoralea corylifolia. It is administered either topically or orally in conjunction with ultraviolet light in the treatment of vitiligo. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

lactone : Any cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

antipsoriatic : A drug used to treat psoriasis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

trioxsalen : 7H-Furo[3,2-g]chromen-7-one in which positions 2, 5, and 9 are substituted by methyl groups. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered orally in conjunction with UV-A for phototherapy treatment of vitiligo. After photoactivation it creates interstrand cross-links in DNA, inhibiting DNA synthesis and cell division, and can lead to cell injury; recovery from the cell injury may be followed by increased melanisation of the epidermis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
PsoraleagenusA plant genus of the family FABACEAE that is a source of psoralen (FICUSIN).[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID5585
CHEMBL ID1475
CHEBI ID28329
SCHEMBL ID1252
MeSH IDM0022009

Synonyms (172)

Synonym
2,5,9-trimethyl-7h-furo(3,2-g)benzopyran-7-one
trioxisalenum
BRD-K54790157-001-06-4
7h-furo[3,2-g][1]benzopyran-7-one, 2,5,9-trimethyl-
KBIO1_000380
DIVK1C_000380
NCI60_038883
SDCCGMLS-0066609.P001
4,8-trimethylpsoralen
7h-furo[3, 2,5,9-trimethyl-
4,8-trimethylpsoralene
lactone
nsc-71047
trisoralen
2,9-trimethyl-7h-furo[3,2-g][1]benzopyran-7-one
5-benzofuranacrylic acid,2,7-trimethyl-, .delta.-lactone
benzofuranacrylic acid,2,7-trimethyl-,
2',8-trimethylpsoralen
trioxsalin
elder 8011
SPECTRUM_000169
MEGXM0_000462
6-hydroxy-beta,2,7-trimethyl-5-benzofuranacrylic acid gamma-lactone
trioxsalen [usan]
4,5',8-trimethylpsoralene
trioxisaleno [inn-spanish]
7h-furo(3,2-g)(1)benzopyran-7-one, 2,5,9-trimethyl-
trioxysalenum [inn-latin]
7-oxo-2,5,9-trimethyl-7h-furo(3,2-g)(1)benzopyron
brn 0221723
2,5,9-trimethyl-7h-furo(3,2-g)(1)benzopyran-7-one
einecs 223-459-0
trioxysalene [inn-french]
nsc 71047
PRESTWICK_148
antipsoriatic
cas-3902-71-4
NCGC00016643-01
IDI1_000380
NCGC00178384-02
NCGC00178384-03
NCGC00178384-01
trimethylpsoralen
2,5,9-trimethyl-7h-furo[3,2-g]chromen-7-one
NSC71047 ,
2,5,9-trimethylfuro[3,2-g]chromen-7-one
ACON1_000251
ACON0_000603
PRESTWICK2_000709
BSPBIO_000897
PRESTWICK3_000709
trioxsalen
3902-71-4
C09314
trioxysalen
4,8,5'-trimethylpsoralen
trioxsalen, >=98% (hplc), powder
DB04571
trioxsalen (usp)
trioxysalen (jan/inn)
trisoralen (tn)
D01034
BPBIO1_000987
NCGC00094804-02
trioxysalenum
trioxisaleno
NCGC00094804-01
2',4,8-trimethylpsoralen
6-hydroxy-beta,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone
CHEBI:28329 ,
trioxysalene
4,5',8-trimethylpsoralen
KBIOGR_001286
KBIO2_003217
KBIOSS_000649
KBIO2_000649
KBIO2_005785
KBIO3_002156
SPECTRUM3_001378
SPBIO_002818
PRESTWICK1_000709
PRESTWICK0_000709
NINDS_000380
SPECTRUM4_000883
SPBIO_001126
SPECTRUM2_001083
SPECTRUM1500596
BSPBIO_002936
OPREA1_203343
SPECTRUM5_001557
MLS001173417
smr000538905
HMS2092A12
T2267
2,5,9-trimethylfuro[3,2-g]benzopyran-7-one
tmp (psoralen)
CHEMBL1475
HMS501C22
HMS1921I05
HMS1570M19
HMS2097M19
A824380
2,5,9-trimethyl-7-furo[3,2-g][1]benzopyranone
HMS2879M06
nsc757371
pharmakon1600-01500596
nsc-757371
dtxcid403716
tox21_110541
dtxsid3023716 ,
CCG-39937
NCGC00016643-02
NCGC00016643-04
NCGC00016643-06
NCGC00016643-05
NCGC00016643-03
y6uy8ov51t ,
trioxysalen [inn]
2,5,9-trimethylpsoralen
trioxsalen [usan:usp]
unii-y6uy8ov51t
5-19-04-00472 (beilstein handbook reference)
FT-0603651
NCGC00016643-10
AKOS015912601
2,5,9-trimethyl-7h-furo[3,2-g][1]benzopyran-7-one
trioxsalen [mi]
trioxsalen [orange book]
trioxysalen [mart.]
trioxysalen [jan]
trioxsalen [usp-rs]
trioxsalen [vandf]
trioxsalen [usp impurity]
trioxysalen [who-dd]
4,5',8-trimethylpsoralen [iarc]
SCHEMBL1252
tox21_110541_1
NCGC00016643-09
KS-5184
CS-4760
4,5,8-trimethylpsoralen
2,5,9-trimethyl-7h-furo[3,2-g]chromen-7-one #
trixsalen
trioxalen
5-benzofuranacrylic acid, 6-hydroxy-.beta.,2,7-trimethyl-, .delta.-lactone
HY-B1157
AB00052119_09
mfcd00005010
4,7,9-trimethyl-2h-furo[3,2-g]chromen-2-one
SR-01000812969-7
SR-01000812969-6
SR-01000812969-5
sr-01000812969
SR-01000812969-2
trioxsalen, united states pharmacopeia (usp) reference standard
SBI-0051547.P002
HMS3714M19
Z1544404499
Q854263
BRD-K54790157-001-10-6
EN300-122631
STL564342
trisoralen;trioxysalen;tmp
T72416
trioxsalen (usp impurity)
2,5,9-trimethyl-7h-furo(3,2-g)chromen-7-one
trioxysalen (mart.)
trioxsalen (usp-rs)
4,5',8-trimethylpsoralen (iarc)
d05ad01
trioxisalene
d05ba01

Research Excerpts

Overview

Trioxsalen (TRX) is a 4,5',8-trimethylated psoralen analog presenting interesting biological activities when irradiated with UVA light.

ExcerptReferenceRelevance
"Trioxsalen (TRX) is a 4,5',8-trimethylated psoralen analog presenting interesting biological activities when irradiated with UVA light. "( Trioxsalen derivatives with lipoxygenase inhibitory activity.
Athanassopoulos, CM; E Bariamis, S; Hadjipavlou-Litina, D; Militsopoulou, M; Papaioannou, D, 2009
)
3.24

Treatment

ExcerptReferenceRelevance
"The trioxsalen-treated RNA had an altered ultraviolet absorption spectrum and a distinctive fluorescence emission spectrum."( Properties of Escherichia coli 16S ribosomal ribonucleic acid treated with 4,5',8-trimethylpsoralen and light.
Champney, WS; Karathanasis, SK, 1979
)
0.74

Toxicity

ExcerptReferenceRelevance
"Long-term use of topical trimethylpsoralen (TMP) psoralen bath plus ultraviolet A (bath PUVA) is considered safe with regard to the risk of skin cancer."( Concentration-dependent phototoxicity in trimethylpsoralen bath psoralen ultraviolet A.
Rantanen, T; Snellman, E, 2001
)
0.31
"A trioxysalen bath is a safe alternative to systemic 8-methoxypsoralen in long-term psoralen plus ultraviolet A (PUVA) treatment."( Kinetics of phototoxicity in trioxysalen bath psoralen plus ultraviolet A photochemotherapy.
Rantanen, T; Snellman, E,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
" Differences in response are often due to the unpredictable pharmacokinetic behaviour of the drug."( Clinical pharmacokinetics of methoxsalen and other psoralens.
de Wolff, FA; Thomas, TV,
)
0.13

Compound-Compound Interactions

ExcerptReferenceRelevance
"Twenty five patients with severe and extensive psoriasis were treated with trimethylpsoralen (trioxsalen) bath plus ultraviolet A (bath PUVA) combined with oral retinoid, etretinate (Ro 10-9359)."( Trimethylpsoralen bath plus ultraviolet A combined with oral retinoid (etretinate) in the treatment of severe psoriasis.
Fräki, JE; Hollmen, A; Väätäinen, N, 1985
)
0.49
"The effect of the anticancer drug cisplatin (alone and in combination with gamma-radiation) on the initiation of DNA synthesis in Friend leukemia cells was studied."( Effect of cisplatin alone and in combination with gamma-radiation on the initiation of DNA synthesis in Friend leukemia cells.
Ganeva, RL; Tzvetkov, LM,
)
0.13

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"Trimethylpsoralen, psoralen and 8-methoxypsoralen were adminstered in 10 mg dosage orally to 37, 29 and 23 patients with vitiligo."( A comparative clinical evaluation of trimethylpsoralen, psoralen and 8-methoxypsoralen in treating vitiligo.
Sehgal, VN, 1975
)
0.25
" It was determined that the highest longwave UV dosage damaged the HSV-2 virion as well as cross-linking the viral DNA."( Herpes simplex virus types 1 and 2 induce shutoff of host protein synthesis by different mechanisms in Friend erythroleukemia cells.
Hill, TM; Sadler, JR; Sinden, RR, 1983
)
0.27
" It is furthermore shown that a dosage resulting in approximately one cross-link per rDNA molecule (21 kbp, two genes) is sufficient to block RNA synthesis."( 8-Methoxypsoralen DNA interstrand cross-linking of the ribosomal RNA genes in Tetrahymena thermophila. Distribution, repair and effect on rRNA synthesis.
Fengquin, X; Nielsen, H; Nielsen, PE; Zhen, W, 1993
)
0.29
"We sought to determine the time-course and dose-response characteristics of erythema induced by topical TMP, and to compare these parameters with those for topical 8-methoxypsoralen (MOP) within patients."( An intraindividual comparative study of psoralen-UVA erythema induced by bath 8-methoxypsoralen and 4, 5', 8-trimethylpsoralen.
Dawe, RS; Ferguson, J; Ibbotson, SH; Man, I; McKinlay, J, 2003
)
0.32
" TMP PUVA had a significantly steeper dose-response curve at 48, 72, and 96 hours compared with 8-MOP PUVA."( An intraindividual comparative study of psoralen-UVA erythema induced by bath 8-methoxypsoralen and 4, 5', 8-trimethylpsoralen.
Dawe, RS; Ferguson, J; Ibbotson, SH; Man, I; McKinlay, J, 2003
)
0.32
" In view of the steeper dose-response curve for TMP PUVA, a lower UVA incremental regimen should be considered compared with that for 8-MOP PUVA."( An intraindividual comparative study of psoralen-UVA erythema induced by bath 8-methoxypsoralen and 4, 5', 8-trimethylpsoralen.
Dawe, RS; Ferguson, J; Ibbotson, SH; Man, I; McKinlay, J, 2003
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
photosensitizing agentA chemical compound that can be excited by light of a specific wavelength and subsequently transfer energy to a chosen reactant. This is commonly molecular oxygen within a cancer tissue, which is converted to (highly rective) singlet state oxygen. This rapidly reacts with any nearby biomolecules, ultimately killing the cancer cells.
dermatologic drugA drug used to treat or prevent skin disorders or for the routine care of skin.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
psoralensA furanocoumarin with a 7H-furo[3,2-g]chromen-7-one skeleton and its substituted derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (43)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency21.19230.003245.467312,589.2998AID2517
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency2.95260.177814.390939.8107AID2147
LuciferasePhotinus pyralis (common eastern firefly)Potency4.36490.007215.758889.3584AID1224835
glp-1 receptor, partialHomo sapiens (human)Potency1.25890.01846.806014.1254AID624417
RAR-related orphan receptor gammaMus musculus (house mouse)Potency3.34480.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency18.34890.004110.890331.5287AID504467
AR proteinHomo sapiens (human)Potency11.23330.000221.22318,912.5098AID1259243; AID1259247; AID743036
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency3.54810.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency8.77500.001022.650876.6163AID1224838; AID1224839; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency2.45450.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency17.24910.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency5.66000.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency4.35560.001530.607315,848.9004AID1224841; AID1259401
pregnane X nuclear receptorHomo sapiens (human)Potency5.95570.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency7.74550.000229.305416,493.5996AID1259244; AID743080; AID743091
Histone H2A.xCricetulus griseus (Chinese hamster)Potency49.19400.039147.5451146.8240AID1224845
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
mitogen-activated protein kinase 1Homo sapiens (human)Potency6.30960.039816.784239.8107AID995
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency5.56600.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency5.30181.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency10.59090.001557.789015,848.9004AID1259244
Glycoprotein hormones alpha chainHomo sapiens (human)Potency5.01194.46688.344810.0000AID624291
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency5.30181.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency5.30181.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency5.30181.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency10.59090.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency5.30181.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency5.30181.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency5.30181.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency5.30181.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency5.30181.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency5.30181.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency5.30181.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency5.30181.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency5.30181.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency5.30181.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency5.30181.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency5.30181.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)2.35600.00011.00768.7800AID625218
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki1.23400.00000.887110.0000AID625218
Bile salt export pumpHomo sapiens (human)IC50 (µMol)525.10000.11007.190310.0000AID1449628
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)0.83100.00002.37899.7700AID625150
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)2.35600.00011.03029.0000AID625218
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki1.23400.00010.954910.0000AID625218
Adenosine receptor A2aHomo sapiens (human)IC50 (µMol)1.31200.00071.559410.0000AID625195
Adenosine receptor A2aHomo sapiens (human)Ki0.73700.00001.06099.7920AID625195
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (107)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (27)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (31)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (74)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID724354Antioxidant activity assessed as inhibition of AAPH-induced linoleic acid lipid peroxidation at 100 uM by spectrophotometric analysis2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID724348Cytotoxicity against human 1BR3 cells assessed as cell viability at 100 uM after 24 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID724356Inhibition of soybean LOX using sodium linoleate as substrate at 100 uM by spectrophotometric analysis2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID304398Photocytotoxicity against UV irradiated human LoVo cells after 24 hrs by MTT assay2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
BINOL-amino acid conjugates as triggerable carriers of DNA-targeted potent photocytotoxic agents.
AID724347Cytotoxicity against human 1BR3 cells assessed as cell viability at 50 uM after 24 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID304402Induction of pBR322 cross-linking after irradiation by alkaline agarose gel assay2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
BINOL-amino acid conjugates as triggerable carriers of DNA-targeted potent photocytotoxic agents.
AID467954Antiproliferative activity against mouse EAC cells assessed as ratio of ID50 of compound to ID50 of 8-methoxypsoralen2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Scoring function for DNA-drug docking of anticancer and antiparasitic compounds based on spectral moments of 2D lattice graphs for molecular dynamics trajectories.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID724349Cytotoxicity against human 1BR3 cells assessed as cell viability at 20 uM after 24 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID724358Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 20 mins by spectrophotometric analysis2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID724357Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 60 mins by spectrophotometric analysis2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID304403Induction of pBR322 cross-linking in absence of irradiation by alkaline agarose gel assay2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
BINOL-amino acid conjugates as triggerable carriers of DNA-targeted potent photocytotoxic agents.
AID724351Cytotoxicity against human 1BR3 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID304400Selectivity index, ratio of CC50 for LoVo cells to EC50 for UV irradiated LoVo cells2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
BINOL-amino acid conjugates as triggerable carriers of DNA-targeted potent photocytotoxic agents.
AID304399Cytotoxicity against human LoVo cells after 24 hrs by MTT assay2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
BINOL-amino acid conjugates as triggerable carriers of DNA-targeted potent photocytotoxic agents.
AID724350Cytotoxicity against human 1BR3 cells assessed as cell viability at 1 uM after 24 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID619965Inhibition of NF-KB p50 subunit/DNA interaction after 20 mins by EMSA2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Development of a novel furocoumarin derivative inhibiting NF-κB dependent biological functions: design, synthesis and biological effects.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID304401Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26
BINOL-amino acid conjugates as triggerable carriers of DNA-targeted potent photocytotoxic agents.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (502)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990285 (56.77)18.7374
1990's122 (24.30)18.2507
2000's46 (9.16)29.6817
2010's37 (7.37)24.3611
2020's12 (2.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.51 (24.57)
Research Supply Index6.29 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index69.41 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (3.08%)5.53%
Reviews10 (1.92%)6.00%
Case Studies6 (1.15%)4.05%
Observational0 (0.00%)0.25%
Other488 (93.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (27)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Phase 2 Trial With a Phase 1 Safety Run-in: Porfimer Sodium Mediated Interstitial Photodynamic Therapy and Standard of Care (SoC) Therapy Versus SoC Therapy Alone for the Treatment of Patients With Locally Advanced or Recurrent Head and Neck [NCT03727061]Phase 282 participants (Anticipated)Interventional2019-07-10Recruiting
Light Dosimetry for Intraoperative Photodynamic Therapy (IO-PDT) With Porfimer Sodium (Photofrin) in Patients With Malignant Mesothelioma or Non-Small Cell Lung Cancer (NSCLC), or Other Malignancies With Pleural Disease - Phase I Study [NCT03678350]Phase 19 participants (Actual)Interventional2021-09-17Active, not recruiting
Two-arm Phase III Trial Comparing Different Time of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer [NCT02628665]Phase 340 participants (Anticipated)Interventional2015-10-31Recruiting
A Pilot Study of Pleural Photodynamic Therapy for Patients With Pleural Malignancy [NCT02106559]0 participants (Actual)Interventional2014-09-04Withdrawn
Photodynamic Therapy With Photofrin® for Treatment of Dysplasia, Carcinoma In Situ and Stage I Carcinoma of the Oral Cavity and the Larynx: A Pilot Study [NCT00530088]30 participants (Actual)Interventional2001-10-31Terminated(stopped due to new competing studies)
Immunobiology of Photodynamic Therapy in Lung Cancer Patients [NCT00754910]35 participants (Actual)Observational2008-12-31Completed
Observational Study for Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma [NCT01506115]11 participants (Actual)Interventional2009-09-30Completed
A Phase II Study of Pleural Photodynamic Therapy for Patients With Non-small Cell Lung Cancer and Pleural Spread [NCT00601848]Phase 29 participants (Actual)Interventional2004-11-30Terminated(stopped due to Poor accrual and change in standards of care)
Pilot Study for the Diagnosis of Head and Neck Cancer: Photofrin and Visible Light [NCT00002964]Phase 20 participants Interventional1995-02-28Completed
Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer [NCT00322699]Phase 1/Phase 222 participants (Actual)Interventional2005-02-28Completed
A Phase II Clinical Trial on the Efficacy of Photodynamic Therapy With Porfimer Sodium (Photofrin®) for Malignant and Pre-Malignant Lesions and Condemned Mucosa Syndrome in the Upper Aerodigestive Tract [NCT00453336]Phase 245 participants (Actual)Interventional2003-06-30Completed
Phase III Randomized Study of Double Plastic Endoprosthesis Insertion With Versus Without Adjuvant Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Patients With Unresectable Stage III-IV Cholangiocarcinoma [NCT00253617]Phase 30 participants (Actual)InterventionalWithdrawn
Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study [NCT00513539]Phase 392 participants (Actual)Interventional2007-07-31Completed
Endobronchial Ultrasound Transbronchial Needle Guided Interstitial Photodynamic Therapy for Palliation of Locally Advanced Lung Cancer and Advanced Cancers Obstructing the Airway -Phase I/II [NCT03735095]Phase 1/Phase 265 participants (Anticipated)Interventional2020-02-12Recruiting
A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] [NCT00118222]Phase 31 participants (Actual)Interventional2005-03-31Completed
Surgery and Intracavitary Photodynamic Therapy (PDT) for the Treatment of Malignant Pleural Mesothelioma; The Use of Light Delivery Fibers With Large Diffusers [NCT00054002]Phase 212 participants (Actual)Interventional1999-03-31Completed
Photodynamic Therapy (PDT) for Poor Prognosis Recurrent/Refractory Malignant Brain Tumors - A Phase I Study [NCT01682746]Phase 15 participants (Actual)Interventional2013-03-31Completed
Open-label, Single-center, Non-randomized, Phase I, Dose-ranging Study of Endoscopic Ultrasound (EUS) Guided Photodynamic Therapy (PDT) With Photofrin® in Locally Advanced Pancreatic Cancer [NCT01770132]Phase 112 participants (Anticipated)Interventional2013-04-19Completed
Interstitial Photodynamic Therapy During Standard Chemotherapy for Palliation of Patients With Head and Neck Squamous Cell Carcinoma - Phase II [NCT02068157]Phase 23 participants (Actual)Interventional2014-04-01Terminated(stopped due to Study no longer has an active IDE)
Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors [NCT00003788]Phase 3270 participants (Anticipated)Interventional1998-04-30Active, not recruiting
A Phase II Study of the Safety and Efficacy of Photodynamic Therapy in Carcinoma in Situ of the Esophagus [NCT00002935]Phase 230 participants (Actual)Interventional1995-10-31Completed
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma [NCT02082522]Phase 328 participants (Actual)Interventional2014-11-12Terminated(stopped due to Accrual rate remaining too low)
A Multicenter, Prospective, Open-label, Non-randomized Single-arm Clinical Study of the Safety and Tissue Response to Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Solid Lung Tumor Prior to Surgical Resection [NCT03344861]Phase 110 participants (Actual)Interventional2017-08-14Completed
Multicenter, Prospective, OL, Single-arm Clinical Study of Safety & Feasibility of Using Navigational Bronchoscopy to Perform Interstitial PD Therapy Using Photofrin® as Treatment in Subjects With Unresectable Solid Tumor in Peripheral Lung [NCT02916745]Phase 15 participants (Actual)Interventional2017-01-26Completed
Single Center, Prospective, Open Label, Single-arm Clinical Study of Safety & Feasibility of Using Navigational Bronchoscopy to Perform Interstitial PD Therapy Using Lipiodol® as a Light Deliver and Photofrin® as Treatment in Subjects With Unresectable So [NCT04753918]Early Phase 13 participants (Anticipated)Interventional2021-03-31Not yet recruiting
Phase II Study of Photodynamic Therapy With PHOTOFRIN (Porfimer Sodium) for Injection in Patients With Malignant Bile Duct Obstruction [NCT00003923]Phase 24 participants (Actual)Interventional1999-03-31Completed
Utilizing Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC) With Pleural Disease or Malignant Pleural Mesothelioma (MPM) - Phase I Study [NCT04836429]Phase 116 participants (Anticipated)Interventional2022-03-10Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00453336 (2) [back to overview]Number of Participants Experiencing Adverse Events
NCT00453336 (2) [back to overview]Number of Patients Achieving Complete or Partial Response 4 Months After Completion of Study Treatment
NCT00530088 (2) [back to overview]Local Toxicity
NCT00530088 (2) [back to overview]Response
NCT02068157 (1) [back to overview]Percentage of Participants With Complete Response or Partial Response According to RECIST v1.1
NCT02082522 (15) [back to overview]Best Overall Tumor Response as Measured by the RECIST 1.1 Criteria (Response Evaluation Criteria in Solid Tumors)
NCT02082522 (15) [back to overview]Change From Baseline in Health-related Quality of Life on the 4- and 7-point EORTC QLQ-C30
NCT02082522 (15) [back to overview]Change From Baseline in Health-related Quality of Life on the 4- and 7-point EORTC QLQ-C30
NCT02082522 (15) [back to overview]Change From Baseline in Health-related Quality of Life on the 4- and 7-point EORTC QLQ-C30
NCT02082522 (15) [back to overview]Change From Baseline in Health-related Quality of Life on the 4- and 7-point EORTC QLQ-C30
NCT02082522 (15) [back to overview]Change From Baseline in Health-related Quality of Life on the 4- and 7-point EORTC QLQ-C30
NCT02082522 (15) [back to overview]Change From Baseline in Health-related Quality of Life on the 4- and 7-point European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30)
NCT02082522 (15) [back to overview]Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)
NCT02082522 (15) [back to overview]Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)
NCT02082522 (15) [back to overview]Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)
NCT02082522 (15) [back to overview]Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)
NCT02082522 (15) [back to overview]Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)
NCT02082522 (15) [back to overview]Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)
NCT02082522 (15) [back to overview]Change From Baseline on Karnofsky Performance Scale (KPS)
NCT02082522 (15) [back to overview]Overall Survival Time
NCT02916745 (27) [back to overview]Performance Status on the Eastern Cooperative Oncology Group (ECOG) Score at Day 30 (30 Days Post Photofrin Injection)
NCT02916745 (27) [back to overview]Performance Status on the Eastern Cooperative Oncology Group (ECOG) Score at Screening (Days -14 to -1). Baseline.
NCT02916745 (27) [back to overview]Safety: Laboratory Test Summaries for Each Subject
NCT02916745 (27) [back to overview]Safety: Number of Participants With Indicated Vital Sign Summaries
NCT02916745 (27) [back to overview]Feasibility to Perform Interstitial-Photodynamic Therapy (i-PDT) Into Tumor
NCT02916745 (27) [back to overview]Safety: Physical Examination Summaries for Each Subject
NCT02916745 (27) [back to overview]Short Form Health Survey (SF-36) Score at Baseline
NCT02916745 (27) [back to overview]Short-Form Health Survey (SF-36) Score at Follow-up Visit at 3 Months.
NCT02916745 (27) [back to overview]Short-Form Health Survey (SF-36) Score at Study Exit (6 Month Visit)
NCT02916745 (27) [back to overview]Skin Photosensitivity as a Adverse Event of Special Interest: Participants With Event
NCT02916745 (27) [back to overview]Tumor Response at 3 Months Post Photodynamic Therapy (PDT)
NCT02916745 (27) [back to overview]Tumor Response at Study Exit (6 Months) Post Photodynamic Therapy (PDT)
NCT02916745 (27) [back to overview]Safety: Number of Participants With Indicated Changes to Pulmonary Function Tests (PFTs) Related to Treatment Emergent Adverse Events
NCT02916745 (27) [back to overview]Number of Subjects With at Least One Serious Adverse Event
NCT02916745 (27) [back to overview]Adverse Events Incidence Indicating Safety of Navigational Bronchoscopy-interstitial-Photodynamic Therapy (i-PDT)
NCT02916745 (27) [back to overview]Health-related Quality of Life on the 4- and 7-point European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire 30 Item (QLQ-C30): 6 Months
NCT02916745 (27) [back to overview]Health-related Quality of Life on the 4- and 7-point European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire 30 Item (QLQ-C30): Baseline
NCT02916745 (27) [back to overview]Health-related Quality of Life on the 4- and 7-point European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire 30 Item (QLQ-C30): Follow-up 3 Months
NCT02916745 (27) [back to overview]Health-related Quality of Life on the 4- Point European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Lung Cancer 13 Item (QLQ-LC13): Baseline Score
NCT02916745 (27) [back to overview]Health-related Quality of Life on the 4- Point European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Lung Cancer 13 Item (QLQ-LC13): Follow-up 3 Month Score
NCT02916745 (27) [back to overview]Health-related Quality of Life on the 4- Point European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Lung Cancer 13 Item (QLQ-LC13): Study Exit (6 Months) Score
NCT02916745 (27) [back to overview]Immunology Markers Concentrations Were Examined as an Exploratory Endpoint. The Change From Baseline Was Reported.
NCT02916745 (27) [back to overview]Number of Participants With Indicated Adverse Events
NCT02916745 (27) [back to overview]Performance Status on the Eastern Cooperative Oncology Group (ECOG) Score at 3 Months Post Photofrin Injection
NCT02916745 (27) [back to overview]Performance Status on the Eastern Cooperative Oncology Group (ECOG) Score at 6 Months Post Photofrin Injection
NCT02916745 (27) [back to overview]Performance Status on the Eastern Cooperative Oncology Group (ECOG) Score at Day 1 (Date of Photofrin Injection).
NCT02916745 (27) [back to overview]Performance Status on the Eastern Cooperative Oncology Group (ECOG) Score at Day 3 (Day of Photodynamic Therapy)
NCT03344861 (18) [back to overview]Macroscopic Tissue Examination
NCT03344861 (18) [back to overview]Microscopic Tissue Examination: Brisk Inflammatory Reaction After Surgery
NCT03344861 (18) [back to overview]Microscopic Tissue Examination: Number of Participants With Acute Alveolar Damage in the Normal Lung After Surgery
NCT03344861 (18) [back to overview]Microscopic Tissue Examination: Number of Participants With Atypical/Reactive Type 2 Pneumocytes in the Normal Lung After Surgery
NCT03344861 (18) [back to overview]Microscopic Tissue Examination: Number of Participants With Hemorrhage Seen After Surgery
NCT03344861 (18) [back to overview]Microscopic Tissue Examination: Number of Participants With Increased Alveolar Macrophages in the Normal Lung After Surgery
NCT03344861 (18) [back to overview]Microscopic Tissue Examination: Number of Participants With Large Vessel Damage Indicated by Fibrinoid Necrosis, Thrombus, Vasculitis in the Normal Lung After Surgery
NCT03344861 (18) [back to overview]Microscopic Tissue Examination: Number of Participants With Mucus Plugging/Mucositis in the Normal Lung After Surgery
NCT03344861 (18) [back to overview]Microscopic Tissue Examination: Number of Participants With Necrosis in the Normal Lung After Surgery
NCT03344861 (18) [back to overview]Microscopic Tissue Examination: Number of Participants With Organizing Pneumonia Pattern in the Normal Lung After Surgery
NCT03344861 (18) [back to overview]Microscopic Tissue Examination: Number of Participants With Pneumonitis in the Normal Lung After Surgery
NCT03344861 (18) [back to overview]Safety: Skin Photosensitivity Events Summaries of Abnormal Findings for Each Subject
NCT03344861 (18) [back to overview]Microscopic Tissue Examination: Percent Tumor Cell Necrosis in Tumor Area After Surgery
NCT03344861 (18) [back to overview]Safety: Vital Sign Summary of Abnormal Findings for Each Subject
NCT03344861 (18) [back to overview]Summary of Microscopic Tissue Examination: Percentage of Participants With Complete Response After Surgery
NCT03344861 (18) [back to overview]Safety: Physical Examination Summaries of Non-normal Findings for Each Subject
NCT03344861 (18) [back to overview]Microscopic Tissue Examination: Number of Participants With Cavitation in Normal Lung Area After Surgery
NCT03344861 (18) [back to overview]Safety: Number of Participants With at Least One Adverse Event

Number of Participants Experiencing Adverse Events

Number of participants enrolled experiencing serious adverse events and/or other non-serious events (NCT00453336)
Timeframe: 6 months

Interventionparticipants (Number)
Single Arm36

[back to top]

Number of Patients Achieving Complete or Partial Response 4 Months After Completion of Study Treatment

Number of subjects achieving complete response or partial response to study treatment according to RECIST Criteria version 1.0. (NCT00453336)
Timeframe: 6 months

Interventionparticipants (Number)
Single Arm32

[back to top]

Local Toxicity

Number of patients with an adverse event (NCT00530088)
Timeframe: 30 days

Interventionparticipants (Number)
Porfimer Sodium29

[back to top]

Response

"Response Rate 9.0 TUMOR RESPONSE 9.1 Tumor response will be evaluated at each follow-up visit. 9.2 Objective Tumor Response 9.21 Complete Response - CR1 Complete absence of visible lesion and negative biopsy. CR2 Complete absence of visible lesions without biopsy. 9.22 Partial Response. Reduction in the lesion size by 50% or more in the maximum size of the initial lesion or reduction in grade of lesion, e.g. severe -> mild dysplasia. Patients that have any physical evidence of residual leukoplakia or erythroplasia will require biopsy.~9.23 No Response. All responses less than a Partial Response are considered as No Response.~9.24 Progressive Disease. Any increase in size of the treated lesion or an increase in grade of the treated lesion, i.e. mild to severe dysplasia." (NCT00530088)
Timeframe: 2 years

Interventionpercentage of participants (Number)
Porfimer Sodium3.5

[back to top]

Percentage of Participants With Complete Response or Partial Response According to RECIST v1.1

Tumor response rate according to Response Evaluation Criteria in Solid Tumors 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT02068157)
Timeframe: Up to 12 months

Interventionpercentage of participants (Number)
Treatment (Porfimer Sodium, Image-guided I-PDT)33

[back to top]

Best Overall Tumor Response as Measured by the RECIST 1.1 Criteria (Response Evaluation Criteria in Solid Tumors)

From the start of the treatment until disease progression or recurrence the RECIST 1.1 criteria are applied (Response Evaluation Criteria in Solid Tumors) (NCT02082522)
Timeframe: Up to 26 months

Interventionpercentage of participants (Number)
Photodynamic Therapy-Photofrin Plus SMC56
Standard Medical Care (SMC)75

[back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top]

Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)

The Karnofsky Performance Scale (KPS) scores range from 0% to 100%. The lower the Karnofsky score, the worse likelihood of survival. A score of 100% means there are no complaints and no evidence of disease. A score of 80% means there is normal activity with effort and some signs or symptoms of disease. A score of 0% means death. (NCT02082522)
Timeframe: Baseline, 13 weeks

Interventionscore on a scale (Mean)
Photodynamic Therapy-Photofrin Plus SMC0.0
Standard Medical Care (SMC)2.5

[back to top]

Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)

The Karnofsky Performance Scale (KPS) scores range from 0% to 100%. The lower the Karnofsky score, the worse likelihood of survival. A score of 100% means there are no complaints and no evidence of disease. A score of 80% means there is normal activity with effort and some signs or symptoms of disease. A score of 0% means death. (NCT02082522)
Timeframe: Baseline, 16 weeks

Interventionscore on a scale (Mean)
Photodynamic Therapy-Photofrin Plus SMC-6.7
Standard Medical Care (SMC)3.3

[back to top]

Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)

The Karnofsky Performance Scale (KPS) scores range from 0% to 100%. The lower the Karnofsky score, the worse likelihood of survival. A score of 100% means there are no complaints and no evidence of disease. A score of 80% means there is normal activity with effort and some signs or symptoms of disease. A score of 0% means death. (NCT02082522)
Timeframe: Baseline, up to 4 weeks

Interventionscore on a scale (Mean)
Photodynamic Therapy-Photofrin Plus SMC1.7
Standard Medical Care (SMC)0

[back to top]

Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)

The Karnofsky Performance Scale scores range from 0% to 100%. The lower the Karnofsky score, the worse likelihood of survival. However, the premature termination of the study does not allow for a meaningful analysis of the scale where 100% means no complaints with no evidence of disease, 80% is normal activity with effort and some signs or symptoms of disease. (NCT02082522)
Timeframe: Baseline, 29 weeks

Interventionscore on a scale (Mean)
Photodynamic Therapy-Photofrin Plus SMC0.0
Standard Medical Care (SMC)2.0

[back to top]

Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)

The Karnofsky Performance Scale scores range from 0% to 100%. The lower the Karnofsky score, the worse likelihood of survival. However, the premature termination of the study does not allow for a meaningful analysis of the scale where 100% means no complaints with no evidence of disease, 80% is normal activity with effort and some signs or symptoms of disease. (NCT02082522)
Timeframe: Baseline, 41 weeks

Interventionscore on a scale (Mean)
Photodynamic Therapy-Photofrin Plus SMC10.0
Standard Medical Care (SMC)0.0

[back to top]

Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)

The Karnofsky Performance Scale scores range from 0% to 100%. The lower the Karnofsky score, the worse likelihood of survival. However, the premature termination of the study does not allow for a meaningful analysis of the scale where 100% means no complaints with no evidence of disease, 80% is normal activity with effort and some signs or symptoms of disease. (NCT02082522)
Timeframe: Baseline, 54 weeks

Interventionscore on a scale (Mean)
Photodynamic Therapy-Photofrin Plus SMC0.0
Standard Medical Care (SMC)0.0

[back to top]

Change From Baseline on Karnofsky Performance Scale (KPS)

The Karnofsky Performance Scale scores range from 0% to 100%. The lower the Karnofsky score, the worse likelihood of survival. However, the premature termination of the study does not allow for a meaningful analysis of the scale where 100% means no complaints with no evidence of disease, 80% is normal activity with effort and some signs or symptoms of disease. (NCT02082522)
Timeframe: Baseline, 7 days

Interventionscore on a scale (Mean)
Photodynamic Therapy-Photofrin Plus SMC-0.7
Standard Medical Care (SMC)0

[back to top]

Overall Survival Time

Time from the date of randomization until the date of death or the last date the subject was known to be alive (NCT02082522)
Timeframe: Up to 26 months

Interventiondays (Median)
Photodynamic Therapy-Photofrin Plus SMC444
Standard Medical Care (SMC)387

[back to top]

Performance Status on the Eastern Cooperative Oncology Group (ECOG) Score at Day 30 (30 Days Post Photofrin Injection)

Measured at Day 3. The Eastern Cooperative Oncology Group (ECOG) scores range from 0 to 5. The lowest values mean a better outcome: 0 is fully active with no performance restrictions; 1 is strenuous physical activity restricted but fully ambulatory and able to carry out light work; 2 is capable of all self-care but unable to carry out any work activities - up and about >50% of waking hours; 3 is capable of only limited self-care and confined to bed or chair >50% of waking hours; and 4 is completely disable, cannot carry out any self-care and totally confined to bed or chair. (NCT02916745)
Timeframe: Day 30

InterventionParticipants (Count of Participants)
ECOG value of 0ECOG value of 1ECOG value of 2ECOG value of 3ECOG value of 4ECOG value of 5
Photodynamic Therapy-Photofrin122000

[back to top]

Performance Status on the Eastern Cooperative Oncology Group (ECOG) Score at Screening (Days -14 to -1). Baseline.

Measured at screening to be the baseline measure. The Eastern Cooperative Oncology Group (ECOG) scores range from 0 to 5. The lowest values mean a better outcome: 0 is fully active with no performance restrictions; 1 is strenuous physical activity restricted but fully ambulatory and able to carry out light work; 2 is capable of all self-care but unable to carry out any work activities - up and about >50% of waking hours; 3 is capable of only limited self-care and confined to bed or chair >50% of waking hours; and 4 is completely disable, cannot carry out any self-care and totally confined to bed or chair. (NCT02916745)
Timeframe: up to day 0 (-14 to -1 days)

InterventionParticipants (Count of Participants)
ECOG value of 0ECOG value of 1ECOG value of 2ECOG value of 3ECOG value of 4ECOG value of 5
Photodynamic Therapy-Photofrin122000

[back to top]

Safety: Laboratory Test Summaries for Each Subject

Safety evaluation includes laboratory tests summarized for each subject with any abnormal lab results considered an Adverse Event to be listed. The investigators commented on any laboratory value outside the normal reference range. If the value was judged to be an Adverse Event, it is listed. The values analysed were: Hematology (Hemoglobin, Hematocrit, White Blood Cell, Red Blood Cell, Platelet Count, Prothrombin Time) and Chemistry (Glucose (random), Blood Urea Nitrogen, Electrolytes (sodium, potassium, chloride), Creatinine, Alkaline Phosphatase, Aspartate Aminotransferase, Alanine Aminotransferase, Total Bilirubin, Albumin, Total Protein) (NCT02916745)
Timeframe: Up to 6 months

InterventionParticipants (Count of Participants)
High post-baseline alkaline phosphataseHigh Alkaline Phosphatase value from baselineHigh post-baseline alanine transaminaseHigh aspartate transaminase from baselineHigh creatinine levels from baselineHigh post-baseline glucose levelsHigh glucose levels from baselineHigh urea nitrogen post baselineHigh protein post baselineHigh post baseline hematocritLow hematocrit values from baselineLow erythrocyte count from baselineHigh erythrocyte count from baselineHigh leukocyte count from baselineHigh leukocyte at baseline & then normal post base
Photodynamic Therapy-Photofrin211121321122111

[back to top]

Safety: Number of Participants With Indicated Vital Sign Summaries

Safety evaluation included vital sign summary for each subject. Vital signs included pulse, blood pressure, temperature and respiration rate. Only clinically relevant results, as per the investigator judgement, are included. These would be vital signs that are out of the normal range but could be considered outside enough to be clinically relevant to the subject's health. (NCT02916745)
Timeframe: Up to 6 months

InterventionParticipants (Count of Participants)
Blood pressure increased study day 180 grade 1Respiratory rate increased study day 180 grade 1Respiratory rate increased day 3 grade 1Heart rate increased day 5 grade 1Blood pressure increased day 31 grade 1
Photodynamic Therapy-Photofrin11111

[back to top]

Feasibility to Perform Interstitial-Photodynamic Therapy (i-PDT) Into Tumor

Number of times photodynamic therapy was delivered into the tumor using navigational bronchoscopy for each subject. (NCT02916745)
Timeframe: Day 3 post-treatment

InterventionParticipants (Count of Participants)
One delivery of PDT into tumorTwo deliveries of PDT into tumorThree deliveries of PDT into tumorFour deliveries of PDT into tumor
Photodynamic Therapy-Photofrin3011

[back to top]

Safety: Physical Examination Summaries for Each Subject

Safety evaluation will include the physical examinations summary of non-normal findings for each subject. (NCT02916745)
Timeframe: Up to 6 months

InterventionParticipants (Count of Participants)
Abnormal eyes at 3 month follow-upAbnormal nose, throat, ears and mouth at day 3Abnormal skin at screeningAbnormal skin at Day 1Abnormal skin at Day 3Abnormal skin at Day 5Abnormal skin at day 10Abnormal skin at day 30Abnormal skin at 3 monthsAbnormal skin at 6 monthsAbnormal respiratory at screeningAbnormal respiratory at day 1Abnormal respiratory at day 3Abnormal respiratory at day 5Abnormal respiratory at day 10Abnormal respiratory at day 30Abnormal respiratory at 3 monthsAbnormal respiratory at 6 monthsAbnormal abdomen/Gastrointestinal Day 1Abnormal abdomen/Gastrointestinal 3 monthsAbnormal neurological at screening
Photodynamic Therapy-Photofrin112221431112221221111

[back to top]

Short Form Health Survey (SF-36) Score at Baseline

The Short-Form Health Survey (SF-36) scores range from 0 to 100, with higher scores indicating better health status. SF-36 evaluates 9 dimensions of Health: physical function, role limitations due to physical health problems, body pain, general health, vitality, social functioning, role limitations due to emotional problems domain, and mental health. Summary is provided in the form of physical component score (PCS) and mental component score (MCS) for each of the timepoints. (NCT02916745)
Timeframe: Baseline

Interventionscore on a scale (Median)
Physical Component Score (PCS)Mental Component Score
Photodynamic Therapy-Photofrin49.2729.47

[back to top]

Short-Form Health Survey (SF-36) Score at Follow-up Visit at 3 Months.

The Short-Form Health Survey (SF-36) scores range from 0 to 100, with higher scores indicating better health status. SF-36 evaluates 9 dimensions of Health: physical function, role limitations due to physical health problems, body pain, general health, vitality, social functioning, role limitations due to emotional problems domain, and mental health. Summary is provided in the form of physical component score (PCS) and mental component score (MCS) for each of the timepoints. (NCT02916745)
Timeframe: up to 3 months

Interventionscore on a scale (Median)
Physical Component Score (PCS)Mental Component Score (MCS)
Photodynamic Therapy-Photofrin46.8330.04

[back to top]

Short-Form Health Survey (SF-36) Score at Study Exit (6 Month Visit)

The Short-Form Health Survey (SF-36) scores range from 0 to 100, with higher scores indicating better health status. SF-36 evaluates 9 dimensions of Health: physical function, role limitations due to physical health problems, body pain, general health, vitality, social functioning, role limitations due to emotional problems domain, and mental health. Summary is provided in the form of physical component score (PCS) and mental component score (MCS) for each of the timepoints. (NCT02916745)
Timeframe: Up to 6 months

Interventionscore on a scale (Median)
Physical Component Score (PCS)Mental Component Score (MCS)
Photodynamic Therapy-Photofrin48.3331.90

[back to top]

Skin Photosensitivity as a Adverse Event of Special Interest: Participants With Event

Adverse Event of special interest was Skin Photosensitivity. Skin photosensitivity was examined because all subjects who receive Photofrin are photosensitive and must observe precautions to avoid exposure of eyes and skin to direct sunlight or bright indoor lights for 30 days or longer. Changes in skin will be assessed by grade of erythema, edema and blistering and will be tabulated by Common Terminology Criteria for Adverse Events (CTCAE) grade in the dermatology/skin category. (NCT02916745)
Timeframe: Up to 6 months

InterventionParticipants (Count of Participants)
Erythema Grade 1 Events; relatedErythema Grade 2 Events; relatedPhotosensitivity Reaction Grade 2; relatedRash grade 1; relatedSkin Exfoliation grade 1; relatedFlushing grade 1; related
Photodynamic Therapy-Photofrin111111

[back to top]

Tumor Response at 3 Months Post Photodynamic Therapy (PDT)

From the start of treatment until 3 months post-treatment measured as per the Modified RECIST (Response Evaluation Criteria in Solid Tumors) Criteria (NCT02916745)
Timeframe: Up to 3 months

InterventionParticipants (Count of Participants)
Complete ResponsePartial ResponseStable ResponseProgression of DiseaseAny response (Complete + Partial)
Photodynamic Therapy-Photofrin10401

[back to top]

Tumor Response at Study Exit (6 Months) Post Photodynamic Therapy (PDT)

From the start of treatment until 6 months post-treatment measured as per the Modified RECIST (Response Evaluation Criteria in Solid Tumors) Criteria (NCT02916745)
Timeframe: Up to 6 months

InterventionParticipants (Count of Participants)
Complete ResponsePartial ResponseStable ResponseProgression of DiseaseAny response (Complete + Partial)
Photodynamic Therapy-Photofrin10311

[back to top] [back to top]

Number of Subjects With at Least One Serious Adverse Event

The number of subjects with at least one serious adverse event are listed. (NCT02916745)
Timeframe: Up to 6 months

InterventionParticipants (Count of Participants)
Photodynamic Therapy-Photofrin0

[back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top] [back to top]

Immunology Markers Concentrations Were Examined as an Exploratory Endpoint. The Change From Baseline Was Reported.

"Distribution of lymphocyte subsets from peripheral blood was determined by flow cytometry. Flow cytometry is a laser-based technique used to detect and measure physical and chemical characteristics of a population of cells or particles. It allows simultaneous multi-parameter analysis of single cells.~The selected markers of interest, representative of the broader markers were: Total Thymus-cells (T-Cells), Cluster of Differentiation 4 (CD4) T cell subsets, and Cluster of Differentiation 9 (CD8) T cell subset, CD4 T Regulatory (T Reg) cells, Natural Killer Cells, Activated T cells, Myeloid-Derived Suppressor Cells (MSCDs), Monocytes. The Percent Gated and Absolute counts were analysed for each marker. Gating allows the analysis to be restricted to a specific size of cells (e.g. lymphocytes) to allow a more specific analysis. Absolute counting quantifies the total number of cells. It is recommended to look at both values to get the full picture." (NCT02916745)
Timeframe: Baseline, 10 days post-treatment

InterventionParticipants (Count of Participants)
CD45+ cells Percent gated increasedCD45+ cells Percent gated decreasedCD45+ cells Absolute Count increasedCD45+ cells Absolute Count decreasedHelper T cells Percent Gated IncreasedHelper T cells Percent Gated DecreasedHelper T cells Percent Gated stayed the sameHelper T cells Absolute counts IncreasedHelper T cells Absolute counts DecreasedCD3+, CD4+ T cells Percent Gated increasedCD3+, CD4+ T cells Percent Gated decreasedCD3+, CD4+ T cells Absolute Counts increasedCD3+, CD4+ T cells Absolute Counts decreasedT Reg Cells Percent Gated increasedT Reg Cells Percent Gated decreasedT Reg Cells Percent Gated similarT Reg Cells Absolute Counts increasedT Reg Cells Absolute Counts decreasedCytotoxic T Cells Percent Gated increasedCytotoxic T Cells Percent Gated decreasedCytotoxic T Cells Percent Gated similarCytotoxic T Cells Absolute Counts increasedCytotoxic T Cells Absolute Counts decreasedNatural Killer Cells Percent Gated increasedNatural Killer Cells Percent Gated decreasedNatural Killer Cells Percent Gated Not DoneNatural Killer Cells Absolute Counts increasedNatural Killer Cells Absolute Counts decreasedatural Killer Cells Absolute Counts Not DoneActivated T Cells Percent Gated IncreasedActivated T Cells Percent Gated DecreasedActivated T Cells Absolute Counts IncreasedActivated T Cells Absolute Counts DecreasedTH17 Cytokines Percent Gated IncreasedTH17 Cytokines Percent Gated DecreasedTH17 Cytokines Percent Gated Not DoneTH17 Cytokines Absolute Counts IncreasedTH17 Cytokines Absolute Counts DecreasedMonocytic MDSCs Percent Gated IncreasedMonocytic MDSCs Percent Gated DecreasedMonocytic MDSCs Absolute Counts IncreasedMonocytic MDSCs Absolute Counts DecreasedGranulocytic MDSCs Percent Gated IncreasedGranulocytic MDSCs Percent Gated DecreasedGranulocytic MDSCs Absolute Counts IncreasedGranulocytic MDSCs Absolute Counts DecreasedMonocytes Percent Gated IncreasedMonocytes Percent Gated DecreasedMonocytes Absolute Counts IncreasedMonocytes Absolute Counts Decreased
Photodynamic Therapy-Photofrin23233111441143111413114212212322312223323232324132

[back to top]

Number of Participants With Indicated Adverse Events

Adverse events (AEs) noted by number of participants with at least one event. An AE was defined as any untoward medical occurrence in a subject during the course of the study, regardless of causal relationship. AEs were coded using MedDRA Version 21.1 (NCT02916745)
Timeframe: Up to 6 months post-treatment

InterventionParticipants with at least one event (Number)
Porphyria Grade 2Eye oedema grade 1Dysphagia grade 1Asthenia Grade 1Oedema peripheral grade 1Fall grade 1Trunk injury grade 1Blood pressure increased grade 1Breath sounds abnormal grade 1Carbon monoxide diffusing capacity decreased gr. 1Creatinine renal clearance abnormal gr. 1Heart rate increased grade 1Oxygen saturation decreased grade 1Pulmonary function test abnormal grade 1Respiratory rate increased grade 1Back pain grade 1Atelectasis grade 1Pleural effusion grade 1Dermatitis grade 1Erythema grade 1Erythema grade 2Hyperkeratosis grade 1Photosensitivity reaction grade 2Pruritus grade 1Rash grade 1Skin exfoliation grade 1Flushing grade 1
Photodynamic Therapy-Photofrin111111121111122121111111111

[back to top]

Performance Status on the Eastern Cooperative Oncology Group (ECOG) Score at 3 Months Post Photofrin Injection

Measured at 3 months. The Eastern Cooperative Oncology Group (ECOG) scores range from 0 to 5. The lowest values mean a better outcome: 0 is fully active with no performance restrictions; 1 is strenuous physical activity restricted but fully ambulatory and able to carry out light work; 2 is capable of all self-care but unable to carry out any work activities - up and about >50% of waking hours; 3 is capable of only limited self-care and confined to bed or chair >50% of waking hours; and 4 is completely disable, cannot carry out any self-care and totally confined to bed or chair. (NCT02916745)
Timeframe: up to 3 months

InterventionParticipants (Count of Participants)
ECOG value of 0ECOG value of 1ECOG value of 2ECOG value of 3ECOG value of 4ECOG value of 5
Photodynamic Therapy-Photofrin221000

[back to top]

Performance Status on the Eastern Cooperative Oncology Group (ECOG) Score at 6 Months Post Photofrin Injection

Measured at 6 months. The Eastern Cooperative Oncology Group (ECOG) scores range from 0 to 5. The lowest values mean a better outcome: 0 is fully active with no performance restrictions; 1 is strenuous physical activity restricted but fully ambulatory and able to carry out light work; 2 is capable of all self-care but unable to carry out any work activities - up and about >50% of waking hours; 3 is capable of only limited self-care and confined to bed or chair >50% of waking hours; and 4 is completely disable, cannot carry out any self-care and totally confined to bed or chair. (NCT02916745)
Timeframe: Up to 6 months

InterventionParticipants (Count of Participants)
ECOG value of 0ECOG value of 1ECOG value of 2ECOG value of 3ECOG value of 4ECOG value of 5
Photodynamic Therapy-Photofrin311000

[back to top]

Performance Status on the Eastern Cooperative Oncology Group (ECOG) Score at Day 1 (Date of Photofrin Injection).

Measured at Day 1 which is day of the photofrin injection. The Eastern Cooperative Oncology Group (ECOG) scores range from 0 to 5. The lowest values mean a better outcome: 0 is fully active with no performance restrictions; 1 is strenuous physical activity restricted but fully ambulatory and able to carry out light work; 2 is capable of all self-care but unable to carry out any work activities - up and about >50% of waking hours; 3 is capable of only limited self-care and confined to bed or chair >50% of waking hours; and 4 is completely disable, cannot carry out any self-care and totally confined to bed or chair. (NCT02916745)
Timeframe: 1 day

InterventionParticipants (Count of Participants)
ECOG value of 0ECOG value of 1ECOG value of 2ECOG value of 3ECOG value of 4ECOG value of 5
Photodynamic Therapy-Photofrin140000

[back to top]

Performance Status on the Eastern Cooperative Oncology Group (ECOG) Score at Day 3 (Day of Photodynamic Therapy)

Measured at Day 3. The Eastern Cooperative Oncology Group (ECOG) scores range from 0 to 5. The lowest values mean a better outcome: 0 is fully active with no performance restrictions; 1 is strenuous physical activity restricted but fully ambulatory and able to carry out light work; 2 is capable of all self-care but unable to carry out any work activities - up and about >50% of waking hours; 3 is capable of only limited self-care and confined to bed or chair >50% of waking hours; and 4 is completely disable, cannot carry out any self-care and totally confined to bed or chair. (NCT02916745)
Timeframe: Day 3

InterventionParticipants (Count of Participants)
ECOG value of 0ECOG value of 1ECOG value of 2ECOG value of 3ECOG value of 4ECOG value of 5
Photodynamic Therapy-Photofrin031000

[back to top]

Macroscopic Tissue Examination

The mean measurement of tumor size after surgery. The largest diameter seen is measured. (NCT03344861)
Timeframe: Day 13 to 18

InterventionCM (Mean)
Photodynamic Therapy-Photofrin2.177

[back to top]

Microscopic Tissue Examination: Brisk Inflammatory Reaction After Surgery

The number of participants showing a brisk inflammatory reaction in the tumor area after surgery. This is determined through a histological examination. Brisk Inflammatory Reaction is defined as lymphocytes that infiltrate diffusely the entire tumor and/or infiltrate across the entire base of the tumor. (NCT03344861)
Timeframe: Day 13 to 18

InterventionParticipants (Count of Participants)
Photodynamic Therapy-Photofrin9

[back to top]

Microscopic Tissue Examination: Number of Participants With Acute Alveolar Damage in the Normal Lung After Surgery

Number of Participants with Acute Alveolar damage in the normal lung after surgery seen during the Microscopic Tissue Examination (NCT03344861)
Timeframe: Day 13 to 18

InterventionParticipants (Count of Participants)
Photodynamic Therapy-Photofrin0

[back to top]

Microscopic Tissue Examination: Number of Participants With Atypical/Reactive Type 2 Pneumocytes in the Normal Lung After Surgery

Number of Participants with Atypical/Reactive Type 2 pneumocytes seen in the normal lung after surgery during the Microscopic Tissue Examination: (NCT03344861)
Timeframe: Day 13 to 18

InterventionParticipants (Count of Participants)
Photodynamic Therapy-Photofrin10

[back to top]

Microscopic Tissue Examination: Number of Participants With Hemorrhage Seen After Surgery

The Number of Participants with hemorrhage seen during the microscopic tissue examination after surgery (NCT03344861)
Timeframe: Day 13 to 18

InterventionParticipants (Count of Participants)
Photodynamic Therapy-Photofrin6

[back to top]

Microscopic Tissue Examination: Number of Participants With Increased Alveolar Macrophages in the Normal Lung After Surgery

The number of participants with increased alveolar macrophages post surgery determined in the microscopic tissue examination. (NCT03344861)
Timeframe: Day 13 to 18

InterventionParticipants (Count of Participants)
Photodynamic Therapy-Photofrin10

[back to top]

Microscopic Tissue Examination: Number of Participants With Large Vessel Damage Indicated by Fibrinoid Necrosis, Thrombus, Vasculitis in the Normal Lung After Surgery

Number of Participants with Large Vessel Damage indicated by fibrinoid necrosis, thrombus, vasculitis in the normal lung after surgery seen during Microscopic Tissue Examination (NCT03344861)
Timeframe: Day 13 to 18

InterventionParticipants (Count of Participants)
Photodynamic Therapy-Photofrin1

[back to top]

Microscopic Tissue Examination: Number of Participants With Mucus Plugging/Mucositis in the Normal Lung After Surgery

Number of Participants with Mucus Plugging/Mucositis seen in the normal lung after surgery during the Microscopic Tissue Examination. (NCT03344861)
Timeframe: Day 13 to 18

InterventionParticipants (Count of Participants)
Photodynamic Therapy-Photofrin0

[back to top]

Microscopic Tissue Examination: Number of Participants With Necrosis in the Normal Lung After Surgery

Number of Participants with Necrosis seen in the normal lung after surgery during the Microscopic Tissue Examination (NCT03344861)
Timeframe: Day 13 to 18

InterventionParticipants (Count of Participants)
Photodynamic Therapy-Photofrin3

[back to top]

Microscopic Tissue Examination: Number of Participants With Organizing Pneumonia Pattern in the Normal Lung After Surgery

Number of Participants with Organizing pneumonia pattern in the normal lung after surgery seen during Microscopic Tissue Examination (NCT03344861)
Timeframe: Day 13 to 18

InterventionParticipants (Count of Participants)
Photodynamic Therapy-Photofrin7

[back to top]

Microscopic Tissue Examination: Number of Participants With Pneumonitis in the Normal Lung After Surgery

The Number of Participants with pneumonitis seen in the normal lung area after surgery following the microscopic tissue examination (NCT03344861)
Timeframe: Day 13 to 18

InterventionParticipants (Count of Participants)
Photodynamic Therapy-Photofrin2

[back to top]

Safety: Skin Photosensitivity Events Summaries of Abnormal Findings for Each Subject

Safety evaluation will include incidence of skin photosensitivity summarized for each subject. (NCT03344861)
Timeframe: 108 days (to 3 months post surgery)

InterventionParticipants (Count of Participants)
Photodynamic Therapy-Photofrin4

[back to top]

Microscopic Tissue Examination: Percent Tumor Cell Necrosis in Tumor Area After Surgery

The mean with standard deviation of the percent of tumor cell necrosis in the tumor area after surgery. The tumor itself was examined after it was removed to determine the percent of necrosis seen. (NCT03344861)
Timeframe: Day 13 to 18

InterventionPercent of tumor (Mean)
Photodynamic Therapy-Photofrin22.0

[back to top]

Safety: Vital Sign Summary of Abnormal Findings for Each Subject

Safety evaluation will include vital sign summary for each subject. Only abnormal counts are included. (NCT03344861)
Timeframe: 108 days (to 3 months post surgery)

InterventionParticipants (Count of Participants)
Photodynamic Therapy-Photofrin0

[back to top]

Summary of Microscopic Tissue Examination: Percentage of Participants With Complete Response After Surgery

The Percentage of Participants with Complete Response in Tumor area (no non-viable/necrotic tumor) after surgery (NCT03344861)
Timeframe: Day 13 to 18

Interventionpercentage of participants (Number)
Photodynamic Therapy-Photofrin20

[back to top]

Safety: Physical Examination Summaries of Non-normal Findings for Each Subject

Safety evaluation will include the physical examinations summary of non-normal findings for each subject. (NCT03344861)
Timeframe: 108 days (to 3 months post surgery)

InterventionParticipants (Count of Participants)
Respiratory abnormal at screeningRespiratory abnormal at Follow-up (Day 103-108)Mouth abnormal at Follow-up (day 103-108)
Photodynamic Therapy-Photofrin131

[back to top]

Microscopic Tissue Examination: Number of Participants With Cavitation in Normal Lung Area After Surgery

The number of participants with cavitation seen in the normal lung area from the microscopic tissue examination after surgery (NCT03344861)
Timeframe: Day 13 to 18

InterventionParticipants (Count of Participants)
Photodynamic Therapy-Photofrin1

[back to top]

Safety: Number of Participants With at Least One Adverse Event

Safety evaluation will include incidence of all adverse events, including serious and non-serious. The count of how many subjects experienced at least one adverse event. (NCT03344861)
Timeframe: 108 days (to 3 months post surgery)

InterventionParticipants (Count of Participants)
Photodynamic Therapy-Photofrin10

[back to top]